MSN: Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability
Tupper reaffirmed 2026 product revenue guidance of $805 million to $825 million, citing a 4% increase year-over-year, driven by Jornay growth and durable revenues from the pain portfolio. Jornay ...
Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability
Earnings call Collegium reported 2025 net revenue of $780.6M, up 24% year-over-year, with adjusted EBITDA rising 15% to $460.5M. Jornay PM prescriptions grew 20% and revenue surged 48%. 2026 guidance ...
Nasdaq: Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community
Nasdaq: Collegium Pharmaceutical to Present Real-World Data on Jornay PM at NAPNAP 46th National Conference
Collegium Pharmaceutical, Inc. announced that it will present two posters featuring real-world data on its ADHD treatment, Jornay PM (methylphenidate HCl), at the NAPNAP National Conference in Chicago ...